Related Experiment Videos
Pharmacologic therapy for fetal arrhythmias
W W Pinsky1, W F Rayburn, M I Evans
1Children's Hospital of Michigan, Wayne State University, Detroit.
Clinical Obstetrics and Gynecology
|June 1, 1991
Summary
Fetal cardiac therapy primarily treats arrhythmias, with digitalis often used for in utero drug treatment. Successful treatment improves fetal prognosis, but outcomes vary based on arrhythmia type and cardiac defects.
Area of Science:
- Cardiology
- Maternal-Fetal Medicine
- Pharmacology
Background:
- Fetal cardiac diagnosis has advanced, but in utero treatment options are limited, mainly to arrhythmias.
- Persistent fetal arrhythmias can lead to intrauterine heart failure, impacting prognosis.
- Current intrauterine therapy relies on transplacental drug administration for fetal arrhythmias.
Purpose of the Study:
- To review current approaches to intrauterine fetal cardiac therapy for arrhythmias.
- To discuss the efficacy and limitations of transplacental drug administration.
- To explore potential future direct fetal therapeutic interventions.
Main Methods:
- Review of case reports and existing literature on fetal cardiac arrhythmia treatment.
- Analysis of pharmacologic agents used for transplacental cardioversion.
- Discussion of outcomes based on arrhythmia type and cardiac structure.
Main Results:
- Digitalis is the most frequently reported agent for fetal cardioversion.
- Transplacental antiarrhythmic agents aim to normalize fetal heart rate (FHR) and prevent heart failure with variable success.
- Direct fetal therapy via injection or infusion is being considered as an alternative to maternal therapy.
Conclusions:
- While transplacental therapy can be effective, outcomes vary, and the reasons for differential response are not fully understood.
- Many fetuses can achieve a satisfactory prognosis with appropriate therapy, contingent on the specific arrhythmia and cardiac defects.
- Further research into direct fetal interventions may offer improved therapeutic options.